ArticleAesthetic plastic surgery2026
Systemic Tacrolimus Attenuates Peri-Implant Capsule Formation and Inflammatory/Fibrotic Signaling in a Rat Silicone Implant Model.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCapsule formation in contact with silicone implants may vary according to the administration of systemic immunosuppressive drugs.
methodsA total of 18 Sprague-Dawley rats that underwent premuscular plane silicone implant insertion were divided into three groups as follows: Group 1, untreated negative control (n = 6); Group 2, treated with tacrolimus (n = 6); and Group 3, treated with dexamethasone as a positive control (n = 6). At 3 months after surgery, the histology and immunochemistry of the capsule tissues were analyzed.
resultsSystemic administration of dexamethasone and tacrolimus successfully reduced capsule thickness and inflammatory marker levels. The aggregation of CD3 (T lymphocytes)- and CD68 (histiocytes)-positive cells around the capsule also reduced.
conclusionsThis study aimed to evaluate whether systemic immunosuppression with tacrolimus modulates peri-implant capsule formation and key inflammatory/fibrotic pathways in a rat silicone implant model. We focused on histologic capsule thickness and immunohistochemical markers representing innate/adaptive immune activation and myofibroblast-driven fibrosis as surrogate measures of early periprosthetic tissue remodeling. NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42521783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.